A Deep Dive On Early Time-to-Tocilizumab

On the latest episode of ASTCT Talks, Rahul Banerjee, MD, advanced fellow of Bone Marrow Transplant/CAR-T Therapy in the Department of Medicine at the University of California (UC) San Francisco, and Nina Shah, MD, associate professor in the Department of Medicine at UC San Francisco, discuss their paper “Early Time-to-Tocilizumab after B Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy in Myeloma.” The paper was co-authored by Shah and Banerjee, along with several colleagues, and was published in ASTCT’s Transplantation and Cellular Therapy Journal in March.

Tune in

ASTCT Talks is the official podcast of the American Society for Transplantation and Cellular Therapy (ASTCT). We chat with industry leaders from all areas of the blood and marrow transplantation and cellular therapy field, including doctors, physician assistants, pharmacists, nurses, administrators, social workers, and more. Like what you hear? Subscribe to ASTCT Talks and never miss an episode.

Reference

Banerjee R, Marsal J, Huang CY, et al. Early Time-to-Tocilizumab after B Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy in Myeloma. Transplant Cell Ther. 2021;27(6):477.e1-477.e7. doi:10.1016/j.jtct.2021.03.004